Last Price | 0.19 | Max Price | 0.69 |
Min Price | 0.19 | 1 Year return | -79.79 |
Sector | Health Care | Subsector | Biotechnology |
Year | Turnover | Total sector | Market share |
---|---|---|---|
2019 | 27 | 141,925 | 0.02 % |
2020 | 7 | 170,231 | 0.00 % |
2021 | 13 | 252,886 | 0.01 % |
2022 | 1 | 238,496 | 0.00 % |
2023 | 0 | 0 | 0.00 % |
No Records Found
No Records Found
No Records Found
The period between December 2015 and December 2016 was a loss-making period for the investors in Poxel. The stock lost around 32 percent. The period between August 2011 and August 2016 was a loss-making period for the investors. The stock lost on average 0 percent. Poxel's net incomes between 2011 and 2015 were very volatile through the time and moved between -8,62 million euros and -11,86 million euros.
The global biotech companies gained around 59 percent over the period 2006-2016. Measured since 2011 the sector is 70 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 59 percent.
The French company didn't pay out any dividends (in the past 5 years).
The French company had ultimo 2015 approximately 25,78 thousand employees on it's payroll.
Last year the balance sheet of the French company was worth 46,85 million euros. 8,82 million euros (18,83 percent of the total balance sheet) was financed by debt.
At the end of 2015 the French company had around 19,48 million stocks listed.
All of Poxel's annual reports are stored here. More information about Poxel can be found it's website. .
Results |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Revenue |
0
|
0
|
5
|
75
|
27
|
7
|
Costs |
12
|
25
|
28
|
73
|
52
|
39
|
Profit |
-12
|
-24
|
-22
|
1
|
-26
|
-32
|
Margin of profit |
-20400.00
|
-34971.43
|
-421.55
|
1.74
|
-96.91
|
-467.40
|
ROI |
-32.19
|
-62.15
|
-115.36
|
2.33
|
-65.76
|
-118.42
|
Balance |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Equity |
38
|
39
|
19
|
56
|
39
|
27
|
Debt |
9
|
11
|
47
|
50
|
33
|
38
|
Total assets |
47
|
50
|
67
|
106
|
72
|
65
|
Solvency |
81.17
|
78.31
|
28.96
|
52.86
|
54.14
|
41.30
|
Cash |
42
|
46
|
54
|
67
|
37
|
40
|
Cashflow |
-10
|
-19
|
8
|
-5
|
-26
|
-26
|
Employees |
0
|
0
|
0
|
0
|
0
|
|
Revenue per employee |
0.0
|
0.0
|
0.0
|
0.0
|
0.0
|
|
Cashflow / Debt |
-1.14
|
-1.73
|
0.17
|
-0.10
|
-0.77
|
-0.67
|
Details |
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|
Price |
13.24
|
6.97
|
6.57
|
5.09
|
12.20
|
Eps |
-1.16
|
-0.97
|
0.05
|
-0.99
|
-1.16
|
Price/earnings-ratio |
-11.41
|
-7.19
|
131.40
|
-5.14
|
-0.16
|
Dividend |
0.0
|
0.0
|
0.0
|
0.0
|
|
Dividend % |
0.00 %
|
0.00 %
|
0.00 %
|
0.00 %
|
|
Payout % |
0.0
|
0.0
|
0.0
|
0.0
|
|
Book value |
1.72
|
0.84
|
2.16
|
1.50
|
0.94
|
Market to book |
0.13
|
0.12
|
0.33
|
0.30
|
4.96
|
Cashflow per stock |
-0.82
|
0.35
|
-0.18
|
-0.99
|
-0.90
|
Stocks |
23
|
23
|
26
|
26
|
28
|
Market Cap |
303.86
|
161.20
|
169.88
|
132.62
|
5.41
|
Date
|
Price
|
---|---|
29 Nov 2024
|
0.19
|
27 Nov 2024
|
0.23
|
13 Nov 2024
|
0.26
|
08 Nov 2024
|
0.27
|
05 Nov 2024
|
0.28
|
31 Oct 2024
|
0.29
|
29 Oct 2024
|
0.32
|
23 Oct 2024
|
0.31
|
19 Oct 2024
|
0.32
|
16 Oct 2024
|
0.33
|
14 Oct 2024
|
0.35
|
05 Oct 2024
|
0.39
|
02 Oct 2024
|
0.36
|
27 Sep 2024
|
0.53
|
20 Sep 2024
|
0.55
|
17 Sep 2024
|
0.53
|
13 Sep 2024
|
0.56
|
28 Aug 2024
|
0.57
|
26 Aug 2024
|
0.58
|
23 Aug 2024
|
0.59
|
11 Aug 2024
|
0.60
|
07 Aug 2024
|
0.69
|
05 Aug 2024
|
0.58
|
01 Aug 2024
|
0.59
|
30 Jul 2024
|
0.62
|
26 Jul 2024
|
0.50
|
23 Jul 2024
|
0.51
|
16 Jul 2024
|
0.52
|
10 Jul 2024
|
0.46
|
09 Jul 2024
|
0.47
|